REPORTS, R.R.O. 1990, Reg. 569
Section 5
Cite as REPORTS, R.R.O. 1990, Reg. 569, s. 5 · current to November 11, 2026 · consolidated from January 1, 2026 · read from e-Laws on November 16, 2026
The text
A report under section 25 or 26 of the Act shall contain the following information in addition to the information required under subsection 1 (1):
1. Syphilis:
i. The date of diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital and the date of admission if the person is admitted to a hospital or the name of the hospital and the date of each visit if the person is seen as an out-patient of the hospital.
iv. Duration, stage and site of infection.
v. Drugs and dosage used for previous treatment, if any, of the infection.
vi. If previous treatment given, the place, date and physician or registered nurse in the extended class responsible for the administration of the treatment.
vii. Current treatment, if any, of the infection, setting out the drugs and dosage used.
viii. If current treatment is being given, the place, date and physician or registered nurse in the extended class responsible for the administration of treatment.
ix. Laboratory findings and investigative tests including, without being limited to, serological tests, microscopic examination and cerebrospinal fluid examinations, together with the results of the tests.
x. Contacts.
xi. Risk factors.
xii. Revoked: O. Reg. 498/17, s. 4 (1).
2. Chancroid, Chlamydia trachomatis infections, Gonorrhoea:
i. The date of diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital.
iv. Place where infection is believed to have been acquired.
v. Contacts.
vi. Revoked: O. Reg. 498/17, s. 4 (2).
vii. The agent of disease.
viii. Medical condition of the person including signs and symptoms of the infection.
ix. The case classification of the person.
x. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
xi. The source of infection including history of exposures.
xii. Risk factors for the disease.
xiii. Travel history, both within and outside Canada.
xiv. Initial treatment, if any, of the infection, including, without being limited to, the drugs and dosage used.
xv. If initial treatment has been given, the place, date and physician or registered nurse in the extended class responsible for administration of treatment.
xvi. Final effective treatment including, without being limited to, the drugs and dosage used.
xvii. If effective treatment has been given, the place, date and physician or registered nurse in the extended class responsible for administration of treatment.
xviii. The date of death and relation of the infection to the cause of death, if the person is deceased.
3. Acquired Immune Deficiency Syndrome (AIDS):
i. The date of diagnosis.
ii. The name and telephone number of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital if the person is admitted to a hospital or is an outpatient.
iv. Medical conditions of the person including laboratory findings and date of onset of symptoms that are indicative of Acquired Immune Deficiency Syndrome.
v. Other medical conditions of the person that may have caused immuno-suppression (exclusion criteria).
vi. Country of birth, date of arrival in Canada, race and residence of the person at onset of illness.
vii. Current status of person infected (alive or dead) (if dead give date of death).
viii. Risk factors.
ix.-xii. Revoked: O. Reg. 498/17, s. 4 (4).
4. Hemorrhagic fevers, including Lassa Fever, Ebola virus disease, Marburg virus disease and Hemorrhagic fevers from other viral causes and Plague:
i. The date of diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital and the date of admission if the person is admitted to a hospital.
iv. Travel history, both within and outside Canada.
v. Exposure to any of the following (Give date and time along with details relating to personal protective equipment used, if any):
A. Known reservoir of the pathogen (for example, bats, rodents, monkeys).
B. Persons with a similar illness.
C. Virus in a laboratory.
vi. Clinical history:
A. Date of onset of illness.
B. Symptoms and signs of the illness.
C. Rule out other causes of febrile illness, including, without being limited to, malaria.
vii. Revoked: O. Reg. 498/17, s. 4 (5).
viii. Laboratory specimens.
A. List all specimens collected by type and date.
B. Name of laboratory where specimens may be located.
ix. State if ambulance was used and date of use.
5. Acute Flaccid Paralysis, Chickenpox (Varicella), Diphtheria, Haemophilus influenza, all types, invasive, Measles, Meningococcal disease, invasive, Mumps, Pertussis (Whooping Cough), Pneumococcal disease, invasive, Poliomyelitis, acute, Rubella, Rubella, congenital syndrome, Tetanus:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. Full vaccination history pertaining to the disease in question, including type of vaccine or vaccines and date or dates of receipt.
vi. The case classification of the person.
vii. Laboratory findings and other investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
x. Completion of the course of treatment, including the major mode of therapy and the treatment compliance.
xi. Place where infection is believed to have been acquired.
xii. The source of infection, including history of exposures and potential for community transmission.
xiii. Risk factors.
xiv. The immigration status and origin of the person, including:
A. Country of birth.
B. Country of last residence.
C. Date of arrival in Canada.
D. Immigration status at time of arrival in Canada.
xv. Travel history, both within and outside Canada.
xvi. The employment details of the person, including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including the classroom.
xviii. Contacts.
xix. Number of contacts traced (excluding Tetanus, Pneumococcal disease, invasive and Acute Flaccid Paralysis).
xx. Outcome:
A. If the person is deceased, date and cause of death.
B. Complications.
C. Absconded — lost to follow-up before treatment completion.
D. Other.
6. Tuberculosis:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. Vaccination history.
D. Reactivation of old disease and years of previous treatment setting out the drugs and dosages used and the dates treatment commenced and ended.
vi. The case classification of the person.
vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, X-ray examination, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
ix. Completion of the course of treatment including the major mode of therapy (Directly Observed Therapy — daily or intermittent or Daily, self-administered) and the treatment compliance estimate (80%, 50-79%, less than 50% or unknown).
x. Risk factors.
xi. The immigration status and origin of the person, including:
A. Country of birth.
B. Country of last residence.
C. Date of arrival in Canada.
D. Unique Client Identifier number (“UCI#”) or Immigration Medical Examination number (“IME#”) if UCI# is unknown.
E. Date reported for medical surveillance (has made contact with, or been contacted by, the health unit, if applicable).
F. Date clinically assessed as per post-landing immigration medical surveillance requirements, if applicable.
G. Immigration status at time of arrival in Canada.
H. Country of birth of parents if person is under 20 years of age and Canadian born non-Indigenous.
xii. The Indigenous status of the person.
xiii. Travel history, both within and outside Canada.
xiv. The employment details of the person, including job title and place of employment.
xv. The name and address of the school the person attends, if applicable, including the classroom.
xvi. Contacts.
xvii. Outcome:
A. If the person is deceased, date of death and cause of death.
B. Complications.
C. Absconded — lost to follow-up before treatment completion.
D. Other.
xviii.-xxv. Revoked: O. Reg. 498/17, s. 4 (7).
7. Group B Streptococcal Disease, neonatal, Ophthalmia Neonatorum:
i. The date of the diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital.
iv. Contacts.
v. Medical condition of the person, including signs and symptoms of the infection.
vi. The case classification of the person.
vii. Laboratory findings and other investigative tests, including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Initial treatment, if any, of the infection, including, without being limited to, the drugs and dosage used.
ix. Final effective treatment, including, without being limited to, the drugs and dosage used.
x. Risk factors.
xi. The date of death and relation of the infection to the cause of death, if deceased.
8. Revoked: O. Reg. 138/18, s. 2 (3).
9. Group A Streptococcal disease, invasive:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person including clinical severity, signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital.
B. The date and duration of isolation, if isolated.
vi. The case classification of the person.
vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
x. Antibiotic resistance, if applicable.
xi. Risk factors.
xii., xiii. Revoked: O. Reg. 498/17, s. 4 (10).
xiv. The employment details of the person including job title and place of employment.
xv. The name and address of the school the person attends, if applicable, including the classroom.
xvi. Contacts.
xvii.- xxi. Revoked: O. Reg. 498/17, s. 4 (11).
xxii. The date of death and relation of the infection to the cause of death, if the person is deceased.
10. Influenza – novel, non-seasonal:
i. The date of diagnosis.
ii. The agent of disease, including subtype.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. Vaccination history.
vi. The case classification of the person.
vii. Laboratory findings, including, without being limited to, antigen detection, culture and viral strain identification, genetic typing and serological tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
x. Risk factors.
xi. Travel history, both within and outside Canada.
xii. The employment details of the person, including job title and place of employment.
xiii. The name and address of the school the person attends, if applicable, including the classroom.
xiv. Contacts.
xv. The date of death and relation of the infection to the cause of death, if the person is deceased.
11. Diseases caused by a novel coronavirus, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS):
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or transferred to another hospital or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. The date and duration of quarantine, if quarantined.
D. Vaccination history.
vi. The case classification of the person.
vii. The date of any change of case classification and details of the change.
viii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination, X-ray examination and cerebrospinal fluid examination, together with the results of the tests.
ix. Association with outbreak and outbreak number, if applicable.
x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
xi. Place where infection is believed to have been acquired.
xii. The source of infection including history of exposures, and potential for community transmission.
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
xv. List places and method of travel within Canada prior to and since the onset of illness.
xvi. The employment details of the person including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including the classroom.
xviii. Health unit responsible for identifying contacts.
xix. Contacts.
xx. Race.
xxi. Income level.
xxii. Household size.
xxiii. Language.
xxiv. Revoked: O. Reg. 498/17, s. 4 (15).
xxv. The date of death and relation of the infection to the cause of death, if deceased.
12. Gastroenteritis and respiratory infection outbreaks in institutions and public hospitals:
i. The name and address of the institution or hospital, as the case may be, and the contact person.
ii. The agent of disease, if known.
iii. The onset date and clinical details of symptoms in first and last cases.
iv. A description of the outbreak and an outbreak definition, including, without being limited to, a description of symptoms and laboratory findings.
v. The date the outbreak was declared and the outbreak number, if applicable.
vi. The date the outbreak was declared over.
vii. The total number of cases in residents or patients and all persons who carry on activities in the facility, including, but not limited to, employees, nurses, students, physicians, registered nurses in the extended class, contract workers and volunteers.
viii. The total number of cases in residents and staff of the institution who were admitted to hospital.
ix. The total number of outbreak-related deaths during the outbreak period.
x. Laboratory findings (etiologic agent/subtyping).
xi. Current treatment, if any, of the residents of the institution exhibiting signs and symptoms consistent with the outbreak, setting out the drugs used and the date treatment commenced.
xii. Measures taken to monitor the institution for signs and symptoms consistent with the outbreak in persons who are residents or staff of the institution, including the line list which shall include the name and location of residents and staff within the institution exhibiting signs and symptoms consistent with the description of the outbreak, including clinical details and when the symptoms commenced.
xiii. Number of residents and staff in the entire institution and in areas of the institution affected by the outbreak.
xiv. The details of any notification made to any other institution or hospital regarding the declaration of an outbreak in the institution or hospital for the purposes of preventing the spread of infection.
xv. Infection control measures utilized to minimize the impact of the outbreak on the residents and staff of the institution and to prevent the spread of the infection, including, but not limited to, influenza immunization, exclusion of non-immunized persons from the institution, the use of antiviral medications, isolation of ill persons, increased environmental sanitation and restriction of visitors.
xvi. For outbreaks in institutions, verification of staff immunization policies.
13. Encephalitis, including primary, viral, post-infectious, vaccine-related, subacute sclerosing panencephalitis, unspecified, and Meningitis, acute:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and the current status of the person including signs and symptoms.
v. The name of the hospital and the date of admission and the date of discharge if the person is admitted to hospital or the name and date of visits if the person is seen as an out-patient of the hospital.
vi. The case classification of the person.
vii. The outcome of the disease.
viii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
ix. Association with outbreak and outbreak number, if applicable.
x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
xi. Place where infection is believed to have been acquired.
xii. The source of infection including history of exposures.
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
xv. Revoked: O. Reg. 498/17, s. 4 (18).
xvi. The employment details of the person including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including classroom.
xviii. The date of death and relation of the infection to the cause of death, if deceased.
14. Hepatitis B, Hepatitis C:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.
v. History of immunization, including number of doses and date of receipt and post exposure prophylaxis, including the use of Hepatitis B immune globulin, as appropriate.
vi. The case classification of the person.
vii. Laboratory findings and investigative tests, including, without being limited to, serological tests, together with the results of the tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. The source of infection including history of exposures.
x. Risk factors.
xi. Place where infection is believed to have been acquired.
xii. Travel history, both within and outside Canada.
xiii. The employment details of the person including job title and place of employment, if applicable.
xiv. The name and address of the school the person attends, if applicable, including classroom.
xv. Contacts.
xvi. Revoked: O. Reg. 498/17, s. 4 (24).
xvii. The date of death and relation of the infection to the cause of death, if deceased.
15. Creutzfeldt-Jakob Disease, all types:
i. The date of the diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital and the date of admission if the person is admitted to a hospital or is seen as an out-patient of the hospital.
iv. Laboratory findings and investigative tests including, without being limited to, 14-3-3 protein test, cerebrospinal fluid examination, microscopic examination, electroencephalogram, magnetic resonance imaging, computerized axial tomography and biopsy, together with the results of the tests.
v. History and physical examination findings of the person.
vi. Dates of organ, blood or blood product donated or received.
vii. Name of institution where performed, and dates, with respect to invasive procedures to person including, without being limited to, lumbar puncture, surgery and endoscopy.
viii. Countries of residence and duration of residence or travel.
ix. Genetic history of transmissible spongiform encephalopathy.
x. Date of death, if the person is deceased.
xi. Autopsy findings.
16. Amebiasis, Anaplasmosis, Anthrax, Babesiosis, Blastomycosis, Botulism, Brucellosis, Campylobacter enteritis, Cholera, Cryptosporidiosis, Cyclosporiasis, Echinococcus multilocularis infection, Food poisoning — all causes, Giardiasis, Hantavirus Pulmonary Syndrome, Hepatitis A viral infections, Legionellosis, Listeriosis, Lyme Disease, Paralytic Shellfish Poisoning, Paratyphoid Fever, Powassan virus, Psittacosis/Ornithosis, Q Fever, Rabies, Salmonellosis, Shigellosis, Trichinosis, Tularemia, Typhoid Fever, Verotoxin-producing E. coli infection indicator conditions, including Haemolytic Uraemic Syndrome (HUS), West Nile Virus Illness, Yersiniosis:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition of the person including signs and symptoms of the infection.
v. The name of the hospital and the date of admission and the date of discharge if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.
vi. The case classification of the person.
vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the dates treatment commenced and ended.
x. Risk factors, including exposure to known reservoirs or vectors, as applicable.
xi. Travel history, both within and outside Canada.
xii. Contacts.
xiii. Revoked: O. Reg. 498/17, s. 4 (27).
xiv. The immigration status and origin of the person, including:
A. Country of birth.
B. Country of last residence.
C. Date of arrival to Canada.
xv. Revoked: O. Reg. 498/17, s. 4 (28).
xvi. The employment details of the person including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including classroom.
xviii. The outcome of the disease.
xix. The date of death and relation of the infection to the cause of death, if the person is deceased.
17. Smallpox and other orthopoxviruses, including monkeypox:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person including signs and symptoms of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or transferred to another hospital or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. The date and duration of quarantine, if quarantined.
D. Vaccination history.
vi. The case classification of the person.
vii. The date of any change of case classification and details of the change.
viii. Laboratory findings and investigative tests including, without being limited to culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
ix. Revoked: O. Reg. 498/17, s. 4 (29).
x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
xi. Place, including geographical location, where infection is believed to have been acquired.
xii. The source of infection including history of exposures and potential for community transmission.
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
xv. Revoked: O. Reg. 498/17, s. 4 (30).
xvi. The employment details of the person including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including the classroom.
xviii. Contacts.
xix.-xxiv. Revoked: O. Reg. 498/17, s. 4 (31).
xxv. The date of death and relation of the infection to the cause of death, if deceased. R.R.O. 1990, Reg. 569, s. 5; O. Reg. 1/05, s. 2; O. Reg. 426/07, s. 4; O. Reg. 148/17, ss. 2, 4; O. Reg. 498/17, s. 4; O. Reg. 138/18, s. 2; O. Reg. 7/20, s. 1; O. Reg. 318/20, s. 1; O. Reg. 744/20, s. 1; O. Reg. 462/22, s. 1; O. Reg. 172/23, s. 1; O. Reg. 277/24, s. 1.
Read the REPORTS on e-Laws ↗
Made under Health Protection and Promotion Act, R.S.O. 1990, c. H.7.